The ASAAP project – a multi-country, multi-site clinical study to evaluate a new malaria triple therapy for children – has its kick-off meeting today in Accra, Ghana. The project is led and coordinated by Dr Oumou Maiga-Ascofaré of the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR; Kumasi, Ghana) under the authority of the Kwame Nkrumah University of Science and Technology. EDCTP is represented at the meeting by Dr Montserrat Blázquez Domingo, Senior project officer.
The press release states that ASAAP’s strategy is to develop: ” new antimalarial regimens by combining currently effective antimalarial drugs having different modes of action, such as Artesunate + Amodiaquine (highly efficacious in Africa) with Atovaquone-Proguanil (so far only prescribed for travelers coming from non-endemic regions). The combination of these three antimalarials can reduce the incidence of and delay parasite resistance to the drugs, thereby prolonging their effectiveness. This strategy will maximize the possibility of a transition to next-generation antimalarials without a lapse in gains made in malaria control.”
ASAAP is funded by EDCTP and the German Federal Ministry for Education and Research (BMBF). EDCTP invested EUR 7.6 million in the project.
This message is based on the ASAAP press release.